Randomized phase II trial of the prophylactic use of celecoxib for the prevention of oxaliplatin-related peripheral vascular pain in Capeox (YCOG1205)

[1]  T. Furihata,et al.  Premedication with fast-acting oxycodone hydrochloride hydrate effectively reduced oxaliplatin-induced severe vascular pain. , 2017, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[2]  Y. Nakatsu,et al.  Celecoxib and 2,5‐dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt/β‐catenin signaling pathway , 2016, Cancer science.

[3]  A. Heydari,et al.  The effect of celecoxib and its combination with imatinib on human HT-29 colorectal cancer cells: Involvement of COX-2, Caspase-3, VEGF and NF-κB genes expression. , 2016, Cellular and molecular biology.

[4]  Y. Yamashita,et al.  Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients , 2015, International Journal of Clinical Oncology.

[5]  F. Mols,et al.  A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration , 2014, Supportive Care in Cancer.

[6]  T. Kiba,et al.  Coadministration of 5% glucose solution and dexamethasone and oxaliplatin-related vascular pain grade: a case study. , 2013, Clinical journal of oncology nursing.

[7]  Y. Yakushijin,et al.  [Preventive trial of preheating administration of oxaliplatin-diluted solution in combination with a hot compress for oxaliplatin-induced venous pain]. , 2013, Gan to kagaku ryoho. Cancer & chemotherapy.

[8]  C. Sakamoto,et al.  Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo‐controlled, double‐blind 2‐week study , 2013, Alimentary pharmacology & therapeutics.

[9]  H. Fujii,et al.  [Reduction of angialgia during peripheral administration of oxaliplatin mixed with dexamethasone]. , 2012, Gan to kagaku ryoho. Cancer & chemotherapy.

[10]  Y. Yamashita,et al.  Dexamethasone as a means for controlling vascular pain caused by the administration of oxaliplatin via the peripheral vein and also for controlling oxaliplatin-induced hypersensitivity reactions. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  N. Petrelli,et al.  Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  F. D. De Braud,et al.  Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  T. Tsujinaka,et al.  [Etiology and management of venous pain during intravenous administration of oxaliplatin]. , 2011, Gan to kagaku ryoho. Cancer & chemotherapy.

[14]  B. Ghai,et al.  Effect of parecoxib pretreatment and venous occlusion on propofol injection pain: a prospective, randomized, double-blinded, placebo-controlled study. , 2010, Journal of clinical anesthesia.

[15]  T. Ruhstaller,et al.  Heated (37°C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy? , 2010, Supportive Care in Cancer.

[16]  T. Hickish,et al.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Zauber,et al.  Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial , 2009, Cancer Prevention Research.

[18]  S. Solomon,et al.  Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: The Cross Trial Safety Analysis , 2008, Circulation.

[19]  N. Petrelli,et al.  Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  F. Takahashi‐Yanaga,et al.  Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. , 2007, Biochemical pharmacology.

[21]  S. Solomon,et al.  Celecoxib for the prevention of sporadic colorectal adenomas. , 2006, The New England journal of medicine.

[22]  S. Solomon,et al.  Celecoxib for the prevention of colorectal adenomatous polyps. , 2006, The New England journal of medicine.

[23]  Marc A Pfeffer,et al.  Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.

[24]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[25]  I. Tannock,et al.  Placebo effects in oncology. , 2003, Journal of the National Cancer Institute.

[26]  C. Rao,et al.  Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. , 2002, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[27]  T. Kuwahara,et al.  Experimental infusion phlebitis: tolerance osmolality of peripheral venous endothelial cells. , 1998, Nutrition.

[28]  E. Ohnhaus,et al.  Methodological problems in the measurement of pain: A comparison between the verbal rating scale and the visual analogue scale , 1975, PAIN.